Markers of the uPA system and common prognostic factors in breast cancer

American Journal of Clinical Pathology

Volumn 128, Issue 1, 2007, Pages 112-117

  Minisini, Alessandro Marco ^a   Fabbro, Dora ^a   Di Loreto, Carla ^a   Pestrin, Marta ^a   Russo, Stefania ^a   Cardellino, Giovanni Gerardo ^a   Andreetta, Claudia ^a   Damante, Giuseppe ^a   Puglisi, Fabio ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Breast cancer; COX 2; Cyclooxygenase 2; PAI 1; PAI 1 polymorphism; Plasminogen activator inhibitor; Plasminogen activator system; uPA; Urokinase plasminogen activator

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGRADATION; EXTRACELLULAR MATRIX; FEMALE; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH; BREAST TUMOR; CHEMISTRY; GENETICS; PATHOLOGY; PROMOTER REGION;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTROGEN; URINARY PLASMINOGEN ACTIVATOR;

EID: 34547127874     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/M0GXVXA89BVLJ5C9     Document Type: Article

References (38)

1. Andreasen PA, Kjoller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1-22.
2. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem. 2004;37:541-548.
3. Umeda T, Eguchi Y, Okino K, et al. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J Pathol. 1997;183:388-397.
4. Harbeck N, Kates RE, Schmitt M, et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer. 2004;5:348-352.
5. Sweep CG, Geurts-Moespot J, Grebenschikov N, et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer. 1998;78:1434-1441.
6. Duffy MJ, O'Grady P, Devaney D, et al. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas: preliminary report. Cancer. 1998;62:531-533.
7. Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost. 1991;17:303-312.
8. Bajou K, Maillard C, Jost M, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene. 2004;23:6986-6990.
9. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000;60:636-643.
10. Konecny G, Untch M, Arboleda J, et al. HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res. 2001;7:2448-2457.
11. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol. 2002;20:1000-1007.
12. Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94:116-128.
13. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456-1466.
14. Eriksson P, Kallin B, van 't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995;92:1851-1855.
15. Castelló R, Espana F, Vazquez C, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res. 2006;117:487-492.
16. Zha S, Yegnasubramanian V, Nelson WG, et al. Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 2004;215:1-20.
17. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001;276:18563-18569.
18. Muller-Decker K, Neufang G, Berger I, et al. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A. 2002;99:12483-12488.
19. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997;94:3336-3340.
20. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716.
21. Li G, Yang T, Yan J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun. 2002;299:886-890.
22. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
23. Takahashi Y, Kawahara F, Noguchi M, et al. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett. 1999;460:145-148.
24. Cho MH, Yoon JH, Jaegal YJ, et al. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. Breast. 2006;15:390-398.
25. Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003;97:2978-2987.
26. Singh B, Berry JA, Shoher A, et al. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol. 2005;26:1393-1399.
27. Henry M, Chomiki N, Scarabin PY, et al. Five frequent polymorphisms of the PAI-1 gene. Arterioscler Thromb Vasc Biol. 1997;17:851-858.
28. Minisini AM, Di Loreto C, Mansutti M, et al. Topoisomerase II alpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer. Cancer Lett. 2005;224:133-139.
29. Elston EW, Ellis IO. Method for grading breast cancer [letter]. J Clin Pathol. 1993;46:189-190.
30. Diamanti-Kandarakis E, Palioniko G, Alexandraki K, et al. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol. 2004;150:793-798.
31. Smolarz B, Blasiak J, Kulig A, et al. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. J Exp Clin Cancer Res. 2001;20:247-252.
32. Alvarez-Millan JJ, Bocos C, Ferrin V, et al. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells. Oncology. 2002;62:286-290.
33. Dublin E, Hanby A, Patel NK, et al. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma; fibroblastic expression has strong associations with tumor pathology. Am J Pathol. 2000;157:1219-1227.
34. Konno H, Baba M, Shoji T, et al. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis. 2002;19:527-534.
35. Ottino P, Bazan HE. Corneal stimulation of MMP-1, -9 and uPA by platelet-activating factor is mediated by cyclooxygenase-2 metabolites. Curr Eye Res. 2001;23:77-85.
36. Nishikawa M, Stapleton PP, Freeman TA, et al. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. J Am Coll Surg. 2004;199:428-435.
37. Sivula A, Talvensaari-Mattila A, Lundin J, et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat. 2005;89;215-220.
38. Evans DM, Sloan Stakleff KD. Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination. Clin Exp Metastasis. 2004;21:339-346.